GCT Expands Operations to Kazakhstan

Oleg Kurilov, MD – GCT General Director in Kazakhstan

As 2020 begins, GCT expands its operations in Asia, adding the Republic of Kazakhstan to its map. Dr. Oleg Kurilov is appointed the GCT General Director in Kazakhstan. He specializes in surgery, urology and nephrology and has a broad expertise working in clinical trials.

Located in Central Asia, Kazakhstan has a population of over 18 million people. It is the world’s largest landlocked country and the ninth largest country in the world. Kazakhstan is part of The Eurasian Economic Union (EAEU). Among many economic and political areas, the union regulates and unifies the pharmaceutical and clinical trials industry. This includes an easier registration of drugs and medical devices, accelerated approval timelines, and a simplified customs and logistics process in other member countries. These advantages make Kazakhstan attractive for both regional and global companies.

In December 2019, the government of Kazakhstan approved the state program for the development and improvement of the country’s Healthcare System for 2020-2050. A significant part of the program is devoted to increasing the number of clinical trials and bringing international clinical trials into the country. Currently, it takes 1 month to receive the approval for a clinical study from the Regulatory Authority. The submission to the Ethics Committee is performed in parallel. This allows study sites to open in just 1.5 months, providing no questions are raised by either authority. It is also worth to mention that all regulatory documentation can be submitted in the Russian language.

“Providing the high quality clinical trial services is always our top priority, and expanding to new regions enhances our operational capabilities. Kazakhstan is a rapidly developing country that is fully compliant with GCP. It is a great option to consider Kazakhstan for a global study to have a diverse patient population and fast enrollment. We are excited to offer this new region to our clients,” – GCT CEO, Dr. Eugene Selivra.

End of Enrollment for Pediatric Phase III Trial

GCT has successfully concluded enrollment for the Phase III pediatric study of rare neurological disease in Russia. Reaching the exact recruitment number, as predicted and in under 1.5 months marks an important milestone for our company and the Sponsor – US Pharma and GCT long term partner. Together, we were able to meet the projected deliverables despite the demanding timelines, sensitive patient group and limited number of sites that treat this devastating condition in Russia. The treatment phase of the study is now well underway according to the protocol schedule.

Phase IV Study in Russia Awarded

GCT is awarded a phase IV study to compare the efficacy and safety of two methods of IP administration in patients with acute sore throat. GCT will be managing study in Russia with aim of enrolling up to 160 patients. Apart from clinical monitoring and site management, GCT will be responsible for the full regulatory support and drug importation. The project is currently in the active start-up stage.

It’s the Holiday Season across the globe…

GCT Photo Collage 2019

… and at this special time of year, we are looking back with appreciation to our partners and friends for their ongoing support. Our global team feels grateful for your trust and loyalty, as we invite you to reflect on the 2019 together with us. Thank you for the opportunity to serve you and work with you. We wish you all the best as you embark on 2020!

From all of us at Global Clinical Trials


Investigator Meeting held for study in Chronic Pancreatitis

Last month, GCT held the Investigator Meeting for the gastroenterology project sponsored by a U.S. Pharma company. The event took place in Warsaw, Poland with 100% attendance from all the 20 Ukrainian and Russian sites. Recruitment is planned to open shortly after the first regulatory approval is received.

Project in Czech Republic Awarded

Global Clinical Trials was selected to provide intense monitoring support for a 3-week study in Czech Republic. Not only did GCT organize the study handover within a week, but also proposed a CRA with relevant and comprehensive experience. Specific CRA expertise is a crucial requirement for the monitoring of the in-vitro diagnostic device trial that will be performed at a specialty lab in Prague.

Investigator Meetings recently held by GCT in Europe

Two investigators meetings were organized to support the start-up of the projects awarded to GCT. The first one took place in Warsaw, Poland, and gathered over 20 sites from 3 European countries for the Phase II Ophthalmology study discussion.

The second was organized in Saint-Petersburg, Russia in early October, and was devoted to the training of sites personnel involved in the pediatric Phase III trial in patients with a rare neurological disorder.

Both studies are in the active start-up.

Approval Received for Clinical Study in Romania

This month, an approval was granted by Romanian National Agency for Medicines and Medical Devices to conduct the study in patients with inoperable liver cancers non-responding to standard therapy. Promising research is being carried out by GCT team in Romania and sponsored by a EU based company. The patient enrollment is expected to start shortly following the Investigator Meeting in Bucharest.

GCT has an extensive Oncology expertise in EU, Russia, Ukraine and USA, and this project is another opportunity for the company to enhance it.

Pictured: Monument of Rebirth in front of the MOH building in Bucharest, Romania, image courtesy by Dennis Jarvis under CC BY-SA 2.0

New office in Hungary

GCT Hungarian team had their first day working at the new office yesterday. Due to the continuous growth in operations and the number of employees, GCT decided to move to a larger, more comfortable facility.

Our new location is:

Fehérvári út 44.,
1113 Budapest

Congratulations to our colleagues in Hungary, and hope you are enjoying the new place!


MOH approval received for Rare Genetic Disorder study in Russia

The regulatory approval to conduct CNS Pediatric study in Russia was received by GCT in under 60 days.

This Phase III study in children and young adults with a rare genetic mutation in the X-chromosome was awarded to GCT earlier this year. Study aims to recruit up to 20 patients with this rare and debilitating disease in Russia alone. GCT is responsible for the site management, providing the full service clinical operations support, logistics and regulatory services.

On average, regulatory approval in Russia may take 3 – 3,5 months. We look forward to the first site initiation for this significant and exciting project.

New office in Poland

As our coverage grows and our local teams expand, Global Clinical Trials office in Poland has moved to a new, larger location on Wednesday, 28th of August 2019.

The new address in Poland is:

Mlądzka 10, 04-136


We look forward to new changes and congratulate our colleagues in Poland on the exciting news!

Phase II gastroenterology global study expansion to Ukraine and Russia

GCT has been awarded a new major project by Kangen Pharmaceuticals – a Phase II parallel-group dose-ranging study to evaluate the safety and efficacy of the drug compared to placebo in patients with chronic pancreatitis. Being the experts in the Eastern Europe for 17 years, our team will be responsible for handling the full range of regulatory activities and regional project management in Russia and Ukraine.

In order to enhance the enrollment and to keep up with the Sponsor’s timelines in the US-based study, GCT has conducted feasibility and offered a strategy to facilitate the recruitment of 164 patients.



Rare CNS Genetic Disorder Study Award

Global Clinical Trials is initiating a new Phase III study in pediatric population in Russia. This important project is the continuation of the existing collaboration between GCT and our long-term partner pharmaceutical company based in the U.S.

It is a double-blind, randomized, placebo-controlled study to be followed by a long-term open-label treatment. The trial will be conducted in children and young adults with a rare genetic mutation in the X-chromosome. GCT is responsible for managing all the centers in Russia, including the full scope of clinical operations, logistics services and regulatory support. The regulatory submission was performed as planned.

The investigational medicinal product has already been studied in more than 1,500 subjects, both adults and children. The studies have shown that it is safe and well-tolerated. Furthermore, the data from the previous Phase II trial, managed regionally by GCT, proves the efficacy of the IP. The majority of the patients qualified for the continued treatment demonstrated reduction in seizures, one of the major symptoms of the disease.




SIVs are completed for the neurodegenerative disease trial


This month GCT team has completed all scheduled Site Initiation Visits for the phase II, double-blind, placebo-controlled study in patients with mild-moderate Alzheimer’s Disease.

This USA based clinical trial aims to evaluate the safety, tolerability and preliminary efficacy of the investigational product.

GCT is responsible for the full scope of services: project management, site management, monitoring, IRB interactions and regulatory support in the U.S.

Pictured: a PET scanner
Image credit: Jens Maus, in public domain

Enrollment opens for an Ophthalmology trial in Russia

We are excited to announce the enrollment launch for the Phase III study in patients with ocular hypertension or primary open-angle glaucoma.

This ophthalmology study is multicentre, investigator-masked, and cross-over. Being a non-inferiority and a comparative trial, it aims to evaluate the efficacy and tolerability of an eye drop solution used to treat increased pressure inside the eye.

Global Clinical Trials is responsible for local project management, regulatory services, site management, and logistics services.

Pictured: a diagram showing the visual field in a patient with glaucoma, measured by a campimeter. Image credit: Pignol23, under CC BY-SA 3.0

Database Lock for Non-Hodgkin’s Lymphoma Study

We are delighted to announce the achievement of a huge milestone in the Non-Hodgkin’s Lymphoma Phase II trial. Database for this oncology study was locked last Thursday, 18 April 2019.

This is a randomized, parallel group multicenter international study. Global Clinical Trials has been responsible for the full support of the trial in Ukraine, including regulatory support, site selection, and monitoring at the Ukrainian sites.

Thank you to everyone participating in the study for your hard work and efforts. Now GCT is preparing for study close-out.

Image credit: Kiev, in public domain

Rare Disease Project in Russia

A multi-center rare disease Phase 3b clinical trial has been recently awarded to GCT. Managed globally by our long term Spanish CRO partner, the study will be also conducted at 2 clinical sites selected in Russia. New trial is designed to assess the safety and the efficacy of the innovative treatment for rare metabolic condition.

Picture credit: Image by Steve Buissinne from Pixabay, in public domain

Cardiac Study Expansion in Russia

GCT is happy to announce the expansion of the Phase III Cardiac Surgery Study in Russia. It is an international study aiming to recruit over 1000 patients worldwide. GCT Russian team is managing regulatory, clinical, and logistics part of the trial. Since 2017 and up until now 1 site from Russia was participating in this multi-national trial sponsored by EU Pharma company, now it will be conducted at 5 Russian sites in total.

Database Locked for the Women’s Health Study

We are glad to announce that the database for the Phase III Women’s Health Study was locked on February 4th after 7 years of trial duration. This is a multi-center, randomized, double-blind study conducted in patients with a previous preterm delivery, for its further prevention. GCT is proud to be managing this trial in Russia, Ukraine, Bulgaria, Hungary and Czech Republic, with a total of 1018 patients randomized in our countries.

GCT would like to thank every one of our team members, that worked hard to achieve this milestone!


Phase-III Ophthalmic Study is Approved within 44 Working Days

The end of the year was marked for GCT team with yet another achievement. Clinical trial approval was received ahead of official timelines for Phase III study, – the whole review process, including Q/A with competent authority, lasted 44 working days.

A multi-centre, randomized, investigator-masked study is designed to evaluate the investigational drug in patients with ocular hypertension or primary open angle glaucoma – conditions in which the measured eye pressure is consistently greater than normal.

GCT team’s proactive approach during the submission and the review stages led to this rapid result.

Subscribe to our mailing list

Marketing Permissions

Please select all the ways you would like to hear from Global Clinical Trials (GCT):

You can unsubscribe at any time by clicking the link in the footer of our emails. Please see our Privacy Policy. We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.


GCT is a CRO experienced in performing clinical research in the USA, Europe, Russia and India.

We are a full-service clinical development provider, offering feasibility analysis, regulatory submission, site selection, project management, monitoring, data management, logistics, and more.

Go social with us

Follow us on social networks:

Privacy policy, Terms of service, Site map, Employees login



© 2001—2020 Global Clinical Trials, LLC

All rights reserved.